Clinician track

ACT for OCD: a clinician's guide to where it fits

A patient asks whether acceptance and commitment therapy (ACT) is a real option for OCD, and an honest answer takes more than a yes. Here is what the trials actually found, and where I'd put ACT while exposure stays central.

Where ACT fits in OCD care

Acceptance and commitment therapy (ACT) has a place in OCD care as an evidence-supported alternative, with exposure and response prevention (ERP) staying the first-line psychological treatment. Randomized trials support ACT, including a 176-person group-format trial against exposure-based CBT. In practice it enters the plan mostly when a patient declines exposure work or has started it and left.

The question usually finds me mid-session. A patient has been reading about ACT on a forum, or perhaps a friend swears by it, and what they're really asking is some version of "I don't think I can do exposure, is this the other way?"

That deserves a straight answer, because ACT isn't fringe. It has randomized controlled trials in OCD, including a recent head-to-head against group CBT built on exposure and response prevention, and few alternatives ever earn that.

Where it belongs is the real question. The International OCD Foundation calls ERP "the first-line psychological treatment" for OCD, on the strength of the evidence behind it, and nothing in the ACT literature has changed that. The ACT record is encouraging but thin, a couple of trials deep. The record behind exposure work is consistent and runs much deeper. So the placement I'd defend in any case discussion is ERP first when the patient will take it, and ACT on the specifics of the patient in front of you.

What ACT adds to exposure

Acceptance and commitment therapy targets the patient's struggle with the obsession rather than the obsession's content. The patient practices making room for the thought and the anxiety, stepping back from the thought as a thought, and committing energy to what they value. Exposure targets the compulsion. ACT works on the fight around it.

Start with what your patient has probably been doing for years before they reach either therapy. An intrusive thought fires, and they fight it. They push it down, or argue with it, or scan for proof it isn't true. From the inside, that fight feels like self-defense. But the fight is exhausting and it never settles the question, and meanwhile the whole day gets organized around the thought. That fight, not the thought itself, is what ACT goes after.

In session, that translates into three kinds of work:

• Acceptance. Making room for the thought and the anxiety it drags in, without obeying either.
• Defusion. Stepping back far enough to see the thought as a thought, a sentence the mind produced, rather than a fact demanding action.
• Values and committed action. Naming what the patient actually cares about, and moving their energy there while the thoughts stay loud.

None of that is exposure, by design. In the 2010 randomized trial, the ACT arm ran with no in-session exposure at all.

And if you're already filing ACT as the off-ramp for your exposure-averse patients, hold on. The trials tested ACT delivered whole, as its own protocol. They didn't test it as a warm-up for ERP, and they didn't test it as the thing you switch to when exposures stall partway up a hierarchy. What ACT adds is a different target, the struggle around the obsession, and there's nothing "softer" about asking a patient to drop the fight with a thought that frightens them.

What the trials actually found

Two randomized trials anchor ACT's evidence in OCD. In 2010, ACT outperformed relaxation training across eight sessions with no in-session exposure. In 2025, a 176-person trial found group ACT non-inferior to group CBT built on exposure and response prevention, with results holding at a year. ERP still holds the deeper evidence base.

In 2010, Twohig and colleagues randomized 79 adults with OCD to ACT or to relaxation training. Eight sessions each, and no in-session exposure in the ACT group. The groups separated. By the end, 46% to 56% of the ACT group counted as responders, meaning clearly better, against 13% to 18% with relaxation training, and the gap held at follow-up.

The authors' own verdict is worth reading, because it's smaller than those numbers. ACT, they wrote, "is worth exploring further as a treatment for OCD." Against relaxation training, that's about the right size. Beating a control isn't beating the standard of care.

The harder test came in 2025. Nielsen and colleagues enrolled 176 patients with OCD in a randomized non-inferiority trial, group ACT in one arm and group CBT built on exposure and response prevention in the other, fourteen weekly sessions either way. Non-inferiority is a narrow question, and it's the right one here. The trial wasn't asking whether ACT wins, just whether it keeps pace with the exposure arm.

It kept pace. In the authors' words, group-delivered ACT was "non-inferior to CBT/ERP in reducing OCD symptoms and improving the quality of life" of the patients, and the result was still holding at six months and at a year.

The cautions are the same ones I'd give a colleague who came back from a conference excited about this study. It's one trial. It tested ACT delivered in groups, so the group format is what the finding covers, and individual-format ACT wasn't tested here. And the authors close on the caveat that matters, writing that ACT "may serve as a viable alternative to CBT/ERP in adults with OCD in outpatient mental health settings, although further replication is necessary."

Put that record next to the shelf of exposure trials and the order doesn't really change. One strong head-to-head showing, behind a smaller early trial, doesn't outweigh the evidence stacked behind exposure work. It earns ACT a real place in OCD care, not the front of the line.

Choosing with the client

A reasonable default for OCD is exposure and response prevention first, because its evidence base runs deepest. Acceptance and commitment therapy enters the conversation on specifics, usually a patient who declines exposure work or who has started it and left. Present it with the evidence at its true size, which means real randomized support and a single group-format head-to-head, with replication still needed.

For what it's worth, here's how the choice runs when it's my patient. ERP first when they'll take it, because it carries the most proof and the best-understood limits, and knowing a treatment's limits going in is its own kind of protection.

ACT enters on facts about the patient, not on novelty. The patient who has declined exposure work outright, or perhaps the one who built a hierarchy twice and left twice. For them the arithmetic decides most of these calls, and it's simple arithmetic. A treatment they'll attend beats a first-line treatment they won't start.

Whichever way the conversation leans, the client gets the evidence as it stands:

• Group ACT kept pace with group exposure-based CBT in one randomized trial, through a year of follow-up.
• An earlier trial found ACT outperformed relaxation training, and its authors called it worth exploring further.
• ERP keeps the deepest evidence base, and the 2025 authors themselves say further replication is necessary.

That list needs no selling, and a client can choose inside it.

Expect the combination question next, from clients and colleagues both. The straight answer is that these trials tested each treatment whole and on protocol. Twohig's ACT arm ran without in-session exposure, and Nielsen's trial kept ACT and exposure-based CBT in separate arms, so nothing here has tested a blend. Blending is a clinical judgment call, and it's worth saying that to the client in exactly those words.

If the client wants to read the comparison in plain language, the patient-facing guide to ERP, inference-based CBT (I-CBT), and ACT covers the same ground at their register. And keep the upstream problem in view, because most adults with even severe OCD who reach a professional aren't receiving treatment specific to OCD at all. That gap is quantified in the treatment gap data.

A clinician weighing ACT against ERP, with both trials in view and neither oversold, is already ahead of the field. Either answer, delivered whole, beats the default most patients get.

Learn the treatment from your patient's side of it

Conicia's CE course (6 CE and CME hours) covers ERP, I-CBT, ACT, and OCD medication strategy by taking you through the complete patient program yourself, reading what your patient or client reads and doing what they do. The clinician dashboard is built to ease the work between sessions and support the treatment you deliver. Board acceptance of CE credit can depend on your license and state.